This content is machine translated Ovarian Cancer Algorithm supports maintenance therapy in advanced stages The standard treatment for newly diagnosed advanced ovarian cancer consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has recently…
View Post 5 min This content is machine translated Multiple Myeloma Focus on first-line therapy The innovation of recent years has long since found its way into first-line therapy in multiple myeloma. Thus, the EHA-ESMO Guidelines were amended accordingly in January. Daratumumab, a monoclonal antibody…
View Post 3 min This content is machine translated Advanced pancreatic cancer First-line therapies in the Real Life Check Currently, gemcitabine plus Nab-paclitaxel and FOLFIRINOX are considered standard first-line therapies for advanced pancreatic cancer. So far, there is no direct comparison of these options. An analysis of the German…
View Post 1 min This content is machine translated Hematologic neoplasms Differentiated diagnostics for effective results Differentiated diagnostic options are designed to enable therapy that is tailored to individual needs. However, in hematologic neoplasms, established treatment options are also effective.
View Post 11 min This content is machine translated Metastatic renal cell carcinoma (mRCC) Individual therapy management improves treatment success Increasing understanding of the pathogenetic relationships of renal cell carcinoma has contributed to the development of new drugs. These specifically interfere with the VEGF, PDGF and mTOR signaling pathways. In…
View Post 6 min This content is machine translated 5th Interdisciplinary Prostate Cancer Symposium Metastatic prostate cancer – New therapeutic options Prostate cancer is the most common male tumor in Western countries and is the second leading cause of cancer-related death in Switzerland. In particular, metastatic castration-resistant prostate cancer (mCRPC) is…
